Home- versus Office-based Buprenorphine Induction: Impact on Opioid and Other Drug Use
Home-based buprenorphine induction is gaining increasing attention, yet adequate description and evaluation of this novel strategy is lacking. Prior analysis showed that 30-day treatment retention was similar among patients choosing home-based versus office-based induction. In this subgroup analysis of the same observational cohort, 79 patients who chose either home-based or office-based induction were assessed to determine the association between induction strategy and drug-use outcomes over 6 months. Data analysis included mixed nonlinear models.
- Compared with office-based induction, participants choosing home-based induction:
- had no significant differences in self-reported opioid use.
- had a greater reduction in self-reported use of other drugs (adjusted odds ratio, 0.05).